Skip to content

Study · Observational study · n = 143 · 2025

5 results

Evaluating the Effect of Cerebrolysin as an Adjuvant to Standard Therapy in Patients with Acute Ischemic Stroke: A Prospective Observational Study.

Kandasamy G, Arumugam V, Orayj K, Alshahrani AM, Alanazi TS, Hmlan A, Venugopal JP

Medicina (Kaunas, Lithuania)26 Aug 2025Cited by 1 (Europe PMC)

PMID41010922 (opens in a new tab)PMCIDPMC12472081 (opens in a new tab)DOI10.3390/medicina61091531 (opens in a new tab)PepBankPUB-41010922
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

Background and Objectives: Acute ischemic stroke is a major cause of disability and mortality. Cerebrolysin, a neuropeptide with neuroprotective and neurotrophic properties, may enhance post-stroke recovery. This study evaluated the impact of adding Cerebrolysin to standard therapy on clinical outcomes in patients with acute ischemic stroke. Materials and Methods: This non-randomized prospective observational study included 143 adults with acute ischemic stroke at Kovai Medical Center and Hospital, Coimbatore (April 2016-May 2018). Participants were divided into two groups: the standard therapy group (n = 70) and the adjuvant therapy group (n = 73), which received Cerebrolysin (30 mL IV daily for 14 days) in addition to standard care. Stroke severity and functional outcomes were evaluated using the National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) at baseline and Day 14. A p Results: Stroke severity improved in both groups, but the adjuvant group demonstrated significantly greater reductions in NIHSS scores from 9.90 ± 2.90 to 3.40 ± 1.40 compared to the standard group, which improved from 10.10 ± 2.80 to 4.80 ± 1.30 (t = 6.19, p < 0.001). Additionally, 43.84% of patients in the adjuvant group shifted to minor stroke severity versus 25.71% in the standard group. Both groups showed significant improvements across all domains of the BI, which assesses activities of daily living (ADL); however, the gains were consistently greater in the adjuvant group (p < 0.001). A higher proportion of patients in the Cerebrolysin group achieved slight dependency (38.36%) or full independence (16.44%), compared to 20% and 5.71% in the standard group, respectively. Conclusions: This prospective observational study suggests that adding Cerebrolysin to standard therapy was associated with greater neurological recovery and functional independence in acute ischemic stroke patients. However, the short follow-up, single-center setting, and lack of randomization limit generalizability. Larger multicenter randomized trials with longer follow-up are needed to confirm these findings.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In acute ischemic stroke, adjunctive Cerebrolysin was linked to greater NIHSS reductions than standard therapy alone.

    In plain wordsIn stroke patients, added Cerebrolysin was linked to greater neurological score reductions than standard therapy alone.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNIHSS reduction
    Study

    n = 143

    Comparator
    Standard therapy
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 mL daily · intravenous · 14 daysAs given in this study (human).

    Measurements

    NIHSS at Day 14 (mean)
    3.4
    Cerebrolysin adjuvant group
    NIHSS at Day 14 (mean)
    4.8
    Standard therapy group
    Baseline NIHSS
    9.9
    Cerebrolysin adjuvant group, baseline to Day 14 reduction
    Baseline NIHSS reported ± component (type not stated)
    2.9
    Cerebrolysin adjuvant group, baseline
    Day 14 NIHSS reported ± component (type not stated)
    1.4
    Cerebrolysin adjuvant group, Day 14
    Baseline NIHSS
    10.1
    Standard therapy group, baseline to Day 14 reduction
    Baseline NIHSS reported ± component (type not stated)
    2.8
    Standard therapy group, baseline
    Day 14 NIHSS reported ± component (type not stated)
    1.3
    Standard therapy group, Day 14

    2 more measurements in the study.

    Source sentences

    Summary
    Stroke severity improved in both groups, but the adjuvant group demonstrated significantly greater reductions in NIHSS scores from 9.90 ± 2.90 to 3.40 ± 1.40 compared to the standard group, which improved from 10.10 ± 2.80 to 4.80 ± 1.30 (t = 6.19, p < 0.001).
    2 context sentences
    Summary · context
    This non-randomized prospective observational study included 143 adults with acute ischemic stroke at Kovai Medical Center and Hospital, Coimbatore (April 2016-May 2018).
    Summary · context
    Participants were divided into two groups: the standard therapy group (n = 70) and the adjuvant therapy group (n = 73), which received Cerebrolysin (30 mL IV daily for 14 days) in addition to standard care.
  2. 02HumanObservational studyEfficacy outcome

    In acute ischemic stroke, 43.84% of patients with adjuvant Cerebrolysin shifted to minor stroke severity versus 25.71% with standard therapy.

    In plain wordsIn stroke patients, 43.84% with added Cerebrolysin shifted to minor stroke severity versus 25.71% with standard therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseMinor stroke severity
    Study

    n = 143

    Comparator
    Standard therapy
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 mL daily · intravenous · 14 daysAs given in this study (human).

    Measurements

    Proportion shifted to minor stroke severity
    43.84%
    Cerebrolysin adjuvant group
    Proportion shifted to minor stroke severity
    25.71%
    Standard therapy group

    Source sentences

    Summary
    Additionally, 43.84% of patients in the adjuvant group shifted to minor stroke severity versus 25.71% in the standard group.
    2 context sentences
    Summary · context
    This non-randomized prospective observational study included 143 adults with acute ischemic stroke at Kovai Medical Center and Hospital, Coimbatore (April 2016-May 2018).
    Summary · context
    Participants were divided into two groups: the standard therapy group (n = 70) and the adjuvant therapy group (n = 73), which received Cerebrolysin (30 mL IV daily for 14 days) in addition to standard care.
  3. 03HumanObservational studyEfficacy outcome

    In acute ischemic stroke, Cerebrolysin was linked to greater gains across Barthel Index domains than standard therapy alone.

    In plain wordsIn stroke patients, added Cerebrolysin was linked to greater daily activity score gains than standard therapy alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBarthel Index domains
    Study

    n = 143

    Comparator
    Standard therapy
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 mL daily · intravenous · 14 daysAs given in this study (human).

    Measurements

    P value
    < 0.001
    Gains across Barthel Index domains, Cerebrolysin adjuvant versus standard therapy, Day 14

    Source sentences

    Summary
    Both groups showed significant improvements across all domains of the BI, which assesses activities of daily living (ADL); however, the gains were consistently greater in the adjuvant group (p < 0.001).
    2 context sentences
    Summary · context
    This non-randomized prospective observational study included 143 adults with acute ischemic stroke at Kovai Medical Center and Hospital, Coimbatore (April 2016-May 2018).
    Summary · context
    Participants were divided into two groups: the standard therapy group (n = 70) and the adjuvant therapy group (n = 73), which received Cerebrolysin (30 mL IV daily for 14 days) in addition to standard care.
  4. 04HumanObservational studyEfficacy outcome

    In acute ischemic stroke, slight dependency occurred in 38.36% with Cerebrolysin versus 20% with standard therapy.

    In plain wordsIn stroke patients, slight dependency occurred in 38.36% with Cerebrolysin versus 20% with standard therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseSlight dependency
    Study

    n = 143

    Comparator
    Standard therapy
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 mL daily · intravenous · 14 daysAs given in this study (human).

    Measurements

    Slight dependency
    38.36%
    Cerebrolysin group
    Slight dependency
    20%
    standard group

    Source sentences

    Summary
    A higher proportion of patients in the Cerebrolysin group achieved slight dependency (38.36%) or full independence (16.44%), compared to 20% and 5.71% in the standard group, respectively.
    2 context sentences
    Summary · context
    This non-randomized prospective observational study included 143 adults with acute ischemic stroke at Kovai Medical Center and Hospital, Coimbatore (April 2016-May 2018).
    Summary · context
    Participants were divided into two groups: the standard therapy group (n = 70) and the adjuvant therapy group (n = 73), which received Cerebrolysin (30 mL IV daily for 14 days) in addition to standard care.
  5. 05HumanObservational studyEfficacy outcome

    In acute ischemic stroke, full independence occurred in 16.44% with Cerebrolysin versus 5.71% with standard therapy.

    In plain wordsIn stroke patients, full independence occurred in 16.44% with Cerebrolysin versus 5.71% with standard therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFull independence
    Study

    n = 143

    Comparator
    Standard therapy
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 mL daily · intravenous · 14 daysAs given in this study (human).

    Measurements

    Full independence
    16.44%
    Cerebrolysin group
    Full independence
    5.71%
    standard group

    Source sentences

    Summary
    A higher proportion of patients in the Cerebrolysin group achieved slight dependency (38.36%) or full independence (16.44%), compared to 20% and 5.71% in the standard group, respectively.
    2 context sentences
    Summary · context
    This non-randomized prospective observational study included 143 adults with acute ischemic stroke at Kovai Medical Center and Hospital, Coimbatore (April 2016-May 2018).
    Summary · context
    Participants were divided into two groups: the standard therapy group (n = 70) and the adjuvant therapy group (n = 73), which received Cerebrolysin (30 mL IV daily for 14 days) in addition to standard care.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.